 4D pharma PLC AIM:DDD, NASDAQ:LBPS said its live biotherapeutic for asthma showed promising signs of clinical activity in the very initial stages of the clinical trial process. Part A of the phase III study was designed to assess the safety and tolerability of MRx-4DP0004 and did so. 